Gyroscope nets £50.4M to advance dry AMD gene therapy

Gyroscope raised £50.4 million ($61.1 million) in a series B round to accelerate the development of its dry AMD gene therapy and build out its manufacturing capabilities.

The round came almost entirely from majority shareholder Syncona Ltd., which invested £48 million in the deal. Existing investor Cambridge Innovation Capital also participated, adding the remaining £2.4 million...